Menten AI

Menten AI is a platform drug discovery company that designs peptide therapeutics for conditions with high unmet medical needs. The company's breakthrough platform leverages protein design, machine learning, and quantum computing to create and accelerate the development of novel therapeutic molecules, from target selection to in vivo efficacy testing in record time. Menten AI develops computational methods integrating classical and quantum techniques for optimizing and simulating molecules, thereby reducing R&D costs and expediting drug delivery to patients.

The Menten AI platform overcomes historical limitations in drug design by developing machine learning-based approaches that leverage first-principle physics-based molecular modeling methods. It can create its own data from first principles and apply machine learning to guide the design and optimization of novel peptides with superior potency, desirable in vitro and in vivo properties. Menten AI's platform is the only computational platform capable of achieving nanomolar potency directly from in silico design.

Menten AI's platform delivers drug-like hit molecules in a single round of design within eight weeks, with an initial focus on peptide macrocycles. These offer advantages of both small molecules and large biologics, enabling the targeting of undruggable and hard-to-drug targets beyond the reach of traditional modalities. The platform has been validated across the preclinical discovery pipeline, with several peptides demonstrating drug-like properties and in vivo efficacy. Menten AI also develops bi-functional peptide drug conjugates for immune-oncology applications.